Search research articles
Contact Us
Filters
Showing results (101-110 of 235) with videos related to
Page
of 24
Sort By:
Cancer Medicine
|
May 7, 2020
Radiation pneumonitis in lung cancer patients treated with chemoradiation plus durvalumab
Narek Shaverdian, Maria Thor, Annemarie F Shepherd, et al.
Science Advances
|
November 23, 2022
Widespread hypertranscription in aggressive human cancers
Matthew Zatzman, Fabio Fuligni, Ryan Ripsman, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 9, 2016
Clinical outcomes with pemetrexed-based systemic therapies in RET-rearranged lung cancers
A Drilon, I Bergagnini, L Delasos, et al.
Nature Communications
|
July 18, 2017
Targeting the differential addiction to anti-apoptotic BCL-2 family for cancer therapy
Akane Inoue-Yamauchi, Paul S Jeng, Kwanghee Kim, et al.
Journal for Immunotherapy of Cancer
|
February 3, 2024
Phase 1/2 study of monalizumab plus durvalumab in patients with advanced solid tumors
Sandip P Patel, Teresa Alonso-Gordoa, Susana Banerjee, et al.
Cancer Immunology Research
|
July 12, 2018
Safety and Efficacy of Re-treating with Immunotherapy after Immune-Related Adverse Events in Patients with NSCLC
Fernando C Santini, Hira Rizvi, Andrew J Plodkowski, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
October 14, 2018
Third-Line Nivolumab Monotherapy in Recurrent SCLC: CheckMate 032
Neal Ready, Anna F Farago, Filippo de Braud, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
March 12, 2016
Phase II Study of a Non-Platinum-Containing Doublet of Paclitaxel and Pemetrexed with Bevacizumab as Initial Therapy for Patients with Advanced Lung Adenocarcinomas
M C Pietanza, Matthew D Hellmann, John J Fiore, et al.
Cancer Cell
|
June 13, 2018
Non-conventional Inhibitory CD4<sup>+</sup>Foxp3<sup>-</sup>PD-1<sup>hi</sup> T Cells as a Biomarker of Immune Checkpoint Blockade Activity
Roberta Zappasodi, Sadna Budhu, Matthew D Hellmann, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 14, 2021
Safety and Immunogenicity of LY3415244, a Bispecific Antibody Against TIM-3 and PD-L1, in Patients With Advanced Solid Tumors
Matthew D Hellmann, Nicoletta Bivi, Boris Calderon, et al.
Page
of 24
Search research articles
Search
Showing results (101-110 of 235) with videos related to
Sort By:
Page
of 24
Cancer Medicine
|
May 7, 2020
Radiation pneumonitis in lung cancer patients treated with chemoradiation plus durvalumab
Narek Shaverdian, Maria Thor, Annemarie F Shepherd, et al.
Science Advances
|
November 23, 2022
Widespread hypertranscription in aggressive human cancers
Matthew Zatzman, Fabio Fuligni, Ryan Ripsman, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 9, 2016
Clinical outcomes with pemetrexed-based systemic therapies in RET-rearranged lung cancers
A Drilon, I Bergagnini, L Delasos, et al.
Nature Communications
|
July 18, 2017
Targeting the differential addiction to anti-apoptotic BCL-2 family for cancer therapy
Akane Inoue-Yamauchi, Paul S Jeng, Kwanghee Kim, et al.
Journal for Immunotherapy of Cancer
|
February 3, 2024
Phase 1/2 study of monalizumab plus durvalumab in patients with advanced solid tumors
Sandip P Patel, Teresa Alonso-Gordoa, Susana Banerjee, et al.
Cancer Immunology Research
|
July 12, 2018
Safety and Efficacy of Re-treating with Immunotherapy after Immune-Related Adverse Events in Patients with NSCLC
Fernando C Santini, Hira Rizvi, Andrew J Plodkowski, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
October 14, 2018
Third-Line Nivolumab Monotherapy in Recurrent SCLC: CheckMate 032
Neal Ready, Anna F Farago, Filippo de Braud, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
March 12, 2016
Phase II Study of a Non-Platinum-Containing Doublet of Paclitaxel and Pemetrexed with Bevacizumab as Initial Therapy for Patients with Advanced Lung Adenocarcinomas
M C Pietanza, Matthew D Hellmann, John J Fiore, et al.
Cancer Cell
|
June 13, 2018
Non-conventional Inhibitory CD4<sup>+</sup>Foxp3<sup>-</sup>PD-1<sup>hi</sup> T Cells as a Biomarker of Immune Checkpoint Blockade Activity
Roberta Zappasodi, Sadna Budhu, Matthew D Hellmann, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 14, 2021
Safety and Immunogenicity of LY3415244, a Bispecific Antibody Against TIM-3 and PD-L1, in Patients With Advanced Solid Tumors
Matthew D Hellmann, Nicoletta Bivi, Boris Calderon, et al.
Page
of 24